Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PDE6D | O43924 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533437 | 0.87 | L3MBTL1 (0.62) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL22775067 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL15890215 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL3498895 | 0.77 | LMNA (0.78) | ALDH1A1MAPTLMNANOTUMSMN1; SMN2 | |
| SCHEMBL31503975 | 0.77 | LMNA (0.78) | ALDH1A1MAPTLMNANOTUMNPC1 | |
| SCHEMBL4283172 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL4288489 | 0.77 | MAPT (0.60) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4279669 | 0.75 | EGFR (0.63) | NPC1RAB9ATP53 | |
| SCHEMBL4288020 | 0.75 | KMT2A (0.62) | ALDH1A1LMNASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL25020926 | 0.75 | ALDH1A1 (0.73) | ALDH1A1MAPTSMN1; SMN2HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | ALDH1A1 694/4885MAPT 868/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.